ViewRay (ViewRay) Debt-to-Asset : 0.37 (As of Mar. 2023)

View and export this data going back to 2014. Start your Free Trial

What is ViewRay Debt-to-Asset?

ViewRay's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $80.7 Mil. ViewRay's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $4.4 Mil. ViewRay's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2023 was $233.2 Mil. ViewRay's debt to asset for the quarter that ended in Mar. 2023 was 0.37.

ViewRay Debt-to-Asset Historical Data

The historical data trend for ViewRay's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViewRay Debt-to-Asset Chart

ViewRay Annual Data

Trend

Nov13

Nov14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.19

0.20

0.26

0.21

0.32

ViewRay Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Asset	Get a 7-Day Free Trial															0.23	0.25	0.26	0.32	0.37

Competitive Comparison of ViewRay's Debt-to-Asset

For the Medical Devices subindustry, ViewRay's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ViewRay's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViewRay's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ViewRay's Debt-to-Asset falls into.

ViewRay Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ViewRay's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.86	+	83.544)	/	271.397
	=	0.32

ViewRay's Debt-to-Asset for the quarter that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(80.692	+	4.441)	/	233.159
	=	0.37

ViewRay (OTCPK:VRAYQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ViewRay Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ViewRay's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ViewRay (ViewRay) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViewRay Inc (OTCPK:VRAYQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1099 18th Street, Suite 3000, Denver, CO, USA, 80202

Website

https://www.viewray.com

ViewRay Inc is a radiation therapy and imaging technology company. It designs, manufactures, and markets radiation therapy systems that provide real-time imaging during radiation treatment. Its product portfolio encompasses The MRIdian linac system, The MRIdian system, the Monte Carlo treatment planning system, etc. The company holds the license for its combination of MRI and radiation therapy technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
B Kristine Johnson	director	366 FERNDALE RD S, WAYZATA MN 55391
Sanket Shah	officer: SVP, General Counsel	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Farhad Fred Ebrahimi	10 percent owner	191 UNIVERSITY BLVD., #246, DENVER CO 80206
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Paul Jr Ziegler	officer: Chief Commercial Officer	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Scott William Drake	director, officer: President and CEO	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Adam Andrew Podbelski	officer: SVP, Customer Services	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Jacob Edward Signoriello	officer: Chief Financial Officer	C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER CO 80202
James F. Dempsey	director, officer: Chief Scientific Officer	C/O VIEWRAY INCORPORATED, 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Burke William P. Mr.	officer: Chief Financial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Susan C Schnabel	director	C/O CREDIT SUISSE FIRST BOSTON, 11 MADISON AVE, NEW YORK NY 10010
Brian K Roberts	director	DIGITAS INC.,, 800 BOYLSTON STREET, BOSTON MA 02199
Zachary William Stassen	officer: Chief Financial Officer	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Daniel Jeffrey Moore	director	100 CYBERONICS BVLD, HOUSTON TX 77058